2月11日，药明生物发布公告，公司截至2025年12月31日止全年度收益将增长约16.7%至人民币217.90亿 元；毛利率将提升约5个百分点至46.0%；经调整毛利将增长至约人民币106.38亿元，同比增长约 25.5%；公司截至2025年12月31日止全年度的利润及归属于公司权益股东的利润将分别增长约45.3%至 人民币57.33亿元及约46.3%至人民币49.08亿元； 以及经调整以股份为基础的薪酬开支、外汇损益、以及股权投资、资产出售、重组损益及相关一次性成 本后，公司非国际财务报告准则经调整纯利将增长约22.0%至人民币65.86亿元。 公告表示，该等增长主要归因于(其中包括)以下因素： (iii) 集团对现有及新增产能的利用，包括欧洲生产基地的产能爬坡； (iv) 集团通过药明生物精益运营管理系统(WBS)及数字化方案实现成本节约与效率改善； (v) (vi)公司通过投资投资组合而获得的投资收益。 （药明生物公告） (编辑：杨燕 林辰) (i) "跟随并赢得分子"战略的成功执行，以及领先的技术平台、行业最佳的项目交付时间及优秀的项目 执行过往记录，推动集团收益增长； (ii) 基于双特异性抗体和A ...

港股频道更多独家策划、专家专栏，免费查阅>> 2月11日，药明生物(2269.HK)高开3.55%报41.44港元。消息面上，公司发盈喜，预期截至2025年12月底止年度，股东应占利 润将增长46.3%至49.08亿元；非国际财务报告准则经调整纯利将增长22%至65.86亿元，收益将增长约16.7%至217.9亿元。 药明生物称，该等增长主要因素包括"跟随并赢得分子"战略的成功执行，以及领先的技术平台、行业最佳的项目交付时间 及优秀的项目执行过往记录，推动集团收益增长；基于双特异性抗体和ADC(抗体偶联药物)等快速发展的技术平台，集团扩 大了对生物药行业提供包括研究和发现服务、IND前开发服务及临床和商业化生产服务等在内的服务范围；集团多个先进技 术所产生的研究服务收益增长；集团对现有及新增产能的利用，包括欧洲生产基地的产能爬坡；集团通过药明生物精益运 营管理系统(WBS)及数字化方案实现成本节约与效率改善；及通过投资投资组合而获得的投资收益。 责任编辑：栎树 ...

公告称，药明生物取得收入的增长源于"跟随并赢得分子"战略的成功执行，以及领先的技术平台、行业 最佳的项目交付时间及优秀的项目执行过往记录等共同推动。其他原因还包括：集团多个先进技术所产 生的研究服务收益增长；对现有及新增产能的利用，包括欧洲生产基地的产能爬坡；精益运营管理系统 及数字化方案实现成本节约与效率改善，以及通过投资组合而获得的投资收益。 药明生物(02269)盈喜后高开逾3%，截至发稿，涨3.55%，报41.44港元，成交额2184.22万港元。 消息面上，药明生物发布公告称，预期该集团于2025年度收益将增长约16.7%，至人民币217.9亿元；毛 利率将同比提升约5个百分点至46%；经调整毛利将同比增长25.5%，至约人民币106.38亿元。利润及归 属于公司权益股东的利润，预计将分别同比增长约45.3%至人民币57.33亿元和约46.3%至人民币49.08亿 元；经调整净利润将同比增长约22%至人民币65.86亿元。 ...

Core Viewpoint - WuXi Biologics (02269) expects a revenue growth of approximately 16.7% to RMB 21.79 billion for the fiscal year 2025, driven by successful execution of its "Follow and Win Molecules" strategy and advanced technology platforms [1] Group 1: Financial Projections - Gross margin is anticipated to increase by about 5 percentage points to 46% [1] - Adjusted gross profit is projected to grow by 25.5% to approximately RMB 10.638 billion [1] - Profit attributable to equity shareholders is expected to rise by approximately 45.3% to RMB 5.733 billion [1] - Adjusted net profit is forecasted to increase by about 22% to RMB 6.586 billion [1] Group 2: Growth Drivers - Revenue growth is attributed to the successful execution of the "Follow and Win Molecules" strategy, leading technology platforms, industry-best project delivery times, and a strong track record in project execution [1] - The integrated CRDMO platform is set to add 209 new comprehensive projects in 2025, bringing the total to a record high of 945 projects [1] - The expansion of services in the biopharmaceutical industry includes research discovery, pre-IND development, clinical, and commercial production, leveraging rapidly developing technologies such as bispecific antibodies and ADCs [1] Group 3: Additional Performance Factors - Performance growth is also driven by increased research service revenue from multiple advanced technologies [2] - Utilization of existing and new production capacities, including ramp-up at European production facilities [2] - Cost savings and efficiency improvements achieved through lean operational management systems and digital solutions, along with investment income from the portfolio [2]

公告称，药明生物取得收入的增长源于"跟随并赢得分子"战略的成功执行，以及领先的技术平台、行业 最佳的项目交付时间及优秀的项目执行过往记录等共同推动。 智通财经APP讯，药明生物（02269）公告，预期该集团于2025年度收益将增长约16.7%，至人民币 217.9亿元；毛利率将同比提升约5个百分点至46%；经调整毛利将同比增长25.5%，至约人民币106.38亿 元。 利润及归属于公司权益股东的利润，预计将分别同比增长约45.3%至人民币57.33亿元和约46.3%至人民 币49.08亿元；经调整净利润将同比增长约22%至人民币65.86亿元。 2025年药明生物一体化CRDMO平台全年新增209个综合项目，综合项目总数达945个创下新高。 本次药明生物在公告提及，基于双特异性抗体和ADC（抗体偶联药物）等快速发展的技术平台，其扩 大了对生物药行业提供包括研究发现、IND前开发及临床和商业化生产等在内的服务范围。 根据公告，药明生物业绩增长的其他原因还包括：集团多个先进技术所产生的研究服务收益增长；对现 有及新增产能的利用，包括欧洲生产基地的产能爬坡；精益运营管理系统及数字化方案实现成本节约与 效率改善，以及 ...

以及经调整以股份为基础的薪酬开支、外汇损益、以及股权投资、资产出售、重组损益及相关一次性成 本后，公司非国际财务报告准则经调整纯利将增长约22.0%至人民币65.86亿元。 该等增长主要归因于(其中包括)以下因素﹕(i)"跟随并赢得分子"战略的成功执行，以及领先的技术平 台、行业最佳的项目交付时间及优秀的项目执行过往记录，推动集团收益增长;(ii)基于双特异性抗体和 ADC(抗体偶联药物)等快速发展的技术平台，集团扩大了对生物药行业提供包括研究和发现服务、IND 前开发服务及临床和商业化生产服务等在内的服务范围;(iii)集团多个先进技术所产生的研究服务收益增 长;(iv)集团对现有及新增产能的利用，包括欧洲生产基地的产能爬坡;(v)集团通过药明生物精益运营管 理系统(WBS)及数字化方案实现成本节约与效率改善;(vi)公司通过投资投资组合而获得的投资收益。 药明生物(02269)发布公告，预期与去年同期比较，公司截至2025年12月31日止全年度收益将增长约 16.7%至人民币217.90亿元;毛利率将提升约5个百分点至46.0%;经调整毛利将增长至约人民币106.38亿 元，同比增长约25.5%;公司截至 ...

公告表示，该等增长主要归因于(其中包括)以下因素：(i)"跟随并赢得分子"战略的成功执行，以及领先 的技术平台、行业最佳的项目交付时间及优秀的项目执行过往记录，推动集团收益增长；(ii)基于双特 异性抗体和ADC(抗体偶联药物)等快速发展的技术平台，集团扩大了对生物药行业提供包括研究和发现 服务、IND前开发服务及临床和商业化生产服务等在内的服务范围；(iii)集团多个先进技术所产生的研 究服务收益增长；(iv)集团对现有及新增产能的利用，包括欧洲生产基地的产能爬坡；(v)集团通过药明 生物精益运营管理系统(WBS)及数字化方案实现成本节约与效率改善；及(vi)公司通过投资投资组合而 获得的投资收益。 格隆汇2月11日丨药明生物(02269.HK)发布公告，公司截至2025年12月31日止全年度收益将增长约16.7% 至人民币217.90亿元；毛利率将提升约5个百分点至46.0%；经调整毛利将增长至约人民币106.38亿元， 同比增长约25.5%；公司截至2025年12月31日止全年度的利润及归属于公司权益股东的利润将分别增长 约45.3%至人民币57.33亿元及约46.3%至人民币49.08亿元；以及经调整 ...

Core Insights - WuXi Biologics (02269) CEO Chen Zhisheng highlighted the company's robust growth trajectory, projecting continued high-speed growth through 2025 with a total of 209 new integrated projects added in the year, approximately half of which are from the U.S. market [1] - The total number of integrated projects reached 945, with bispecific antibodies contributing nearly 20% to the total revenue, showing a year-on-year growth of over 120% [1] - The execution of the "Follow and Win Molecules" strategy has led to a total of 99 projects in clinical phase III and commercial production, indicating a potential acceleration in commercial production business [1] Business Performance - The upfront and total payment amounts for research services reached new highs, with potential milestone payments from last year's collaborative projects exceeding $4 billion [1] - WuXi Biologics is accelerating its global expansion, having established a presence in Qatar to serve the Middle East, following its operations in China, the U.S., Ireland, Germany, and Singapore [1] - The company aims to enhance customer experience and delivery efficiency through industry-leading digital CRDMO solutions [1] Future Outlook - The materials indicate that WuXi Biologics is expected to achieve accelerated growth by 2026 [1]

Core Insights - WuXi Biologics (02269) CEO Chen Zhisheng presented at the 44th J.P. Morgan Healthcare Conference, highlighting the company's expected rapid growth in 2025 with a total of 209 new integrated projects in its CRDMO platform, approximately half of which are from the U.S. market [1] - The total number of integrated projects is projected to reach 945, with bispecific antibodies contributing nearly 20% to the total revenue, showing a year-on-year growth of over 120% [1] - The execution of the "Follow and Win Molecule" strategy continues, with a total of 99 projects in clinical phase III and commercial production, indicating potential acceleration in commercial production business [1] - The research services segment has achieved record high upfront and total payment amounts, with potential milestone payments from last year's collaborative projects exceeding $4 billion [1] - WuXi Biologics is accelerating its global expansion, having established a presence in Qatar to serve the Middle East, following its operations in China, the U.S., Ireland, Germany, and Singapore [1] - The company aims to enhance customer experience and delivery efficiency through industry-leading digital CRDMO solutions, with expectations for accelerated growth in 2026 [1]

Core Insights - WuXi Biologics reported a 16.1% year-on-year revenue growth to 9.95 billion yuan for the first half of 2025, driven by the successful execution of its "Follow and Win Molecule" strategy and expansion of service offerings in the biopharmaceutical industry [1] - The company's IFRS net profit increased by 54.8% to 2.76 billion yuan, with profit attributable to shareholders rising by 56.0% to 2.34 billion yuan, primarily due to gross profit growth and returns from investments and asset optimization [1] - WuXi Biologics added 86 comprehensive development projects in the first half of 2025, with over 70% of new projects involving bispecific/multispecific antibodies and ADCs [1] Financial Performance - The company supported 67 clinical phase III projects and 24 commercial production projects as of June 30, 2025, with a 24.9% year-on-year increase in revenue from clinical phase III and commercial production, indicating a maturation of early projects and ongoing growth of existing commercial projects [2] - WuXi Biologics has a total unfulfilled order backlog of 20.34 billion USD, with unfulfilled service orders and potential milestone payment orders amounting to 11.35 billion USD and 9 billion USD, respectively [2] - The unfulfilled orders over the next three years increased from 3.65 billion USD in December 2024 to 4.21 billion USD, reinforcing expectations for near-term revenue growth [2] Future Outlook - Based on current performance, WuXi Biologics has raised its full-year revenue guidance for 2025 [3]